Pharmaceutical Information Network
Search Us Ask Us
What's New!

Publications
AHCPR Research Activities
Medical Sciences Bulletin®
MedWatch News
PNN Pharmacotherapy Line
Other Publications

PharmInfoNet UnCover Reveal Gateway

Drug Information
DrugDB | DrugFAQs | DrugPR

Visit the Glossary
A B C D E F G H I J K L
M N O P Q R S T U V W X Y Z

Disease Centers
Asthma | Cancer | Cardiovascular | Diabetes | Digestive | Endocrine and Metabolic | GERD | Immunology /Allergy | Mental Health/CNS | Obesity | Respiratory

Asthma Information Center Meeting Highlights
62nd Annual ACG Meeting

Discussion Groups
Cardiology | Diabetes | Gastrointestinal | Clinical Trials | MedWebmasters | PharmInfoBYTES | Vascular Biology

Thrombolytic (Vascular) Biology Discussion List

PharmMall
CROs | Consultants | Drug Info | Internet Svcs | Manufacturers | Publishers | Software

ElizaTips

PharmLinks
Biotech | Drug Info | R & D | Medical | Pharmaceutical | Government | Associations | Schools | Pharmcos

Gallery
Antique Pharmacy Jars | Crystal Apothecary | Engravings | Molecular Graphics | Photos

MedWatch

Internet Healthcare Coalition

Welcome to PharmInfoNet!

Sponsorship Options Announcements Contents

Test Your EKG Knowledge


7 January 1998: Focus On Thalidomide

Avoid During Pregnancy Thalidomide Gets a Second Chance
In the early 1960s the very mention of the word "thalidomide" was enough to conjure up the vision of a parent's worst nightmare: the birth of a deformed child. During that period, approximately 8,000 babies were born in Europe with severe defects after their mothers had taken thalidomide. Today, almost 40 years later, manufacturers are conducting clinical trials to see if thalidomide can treat inflammation common to a host of diseases, and combat weight loss and aphthous ulcers in AIDS patients. Other trials are studying thalidomide's effect on the eye disease macular degeneration; on breast, prostate and brain cancer; and on Kaposi's sarcoma (a form of cancer common in AIDS patients). And, the FDA has recently issued an approvable letter (final procedural agreements with the manufacturer are in process) for the use of thalidomide in the treatment of ENL (type II lepra reaction), which is a serious, severe complication of leprosy. continued...

Also see:


* MedWatch: FDA APPROVES ALLEGRA-D

Visit our Awards Page

PharmInfoNet has received dozens of awards and badges of distinction! See what other people are saying about us. We think you will agree that PharmInfoNet is one of the very best sources of health and drug information on the Internet.

Among the awards we have received are:
Awards


New additions ...

Webmaster's Report

Medical Sciences Bulletin

MedWatch News

CARDIO-CONSULT Archive


Pharmaceutical Information Network

Advertising/Sponsorship Options

A service provided by
VirSci Corporation

Mission Statement | Editorial Board | Expert Panel | Disclaimer

Webmaster


We subscribe to the HONcode principles of the Health On the Net Foundation

Copyright©1995-1997. VirSci Corporation. All rights reserved.
PharmInfoNet is owned and operated by VirSci Corporation,
a company not associated with any pharmaceutical company.


Last modified on Monday, 29-Dec-97 16:49:13